TouchNEUROLOGY recently caught up with world renowned researcher in Alzheimer's disease (AD) Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden) who is a member of the TouchNeurology Editorial Board. He gave his perspective on targeting Beta-amyloid for treatment of early AD. Watch the interview, here: https://touchneurology.com/alzheimers-disease-dementia/conference-hub/bengt-winblad-ean-2020-targeting-beta-amyloid-for-the-treatment-of-early-alzheimers/
